With this it has strengthened its presence in the Middle-East. Ranbaxy has now become the first Indian pharma company to have a strong presence in the Middle-East with operations in 11 countries, the company said in a filing to the Bombay Stock Exchange.
"Yemen is important market for us and we are extremely delighted to be here," Ranbaxy Senior Vice President and Regional Director Sanjeev I Dani said.
The company has a strong productline with over 160 approvals so far in Yemen. It has commenced operation by introducing products to more than 350 doctors in the country.
Ranbaxy would focus more on therapeutic areas such as anti-infectives, gastro-intestine, cholesterol lowering and anti-allergic in the country.
It has also become the first company to be registered in Saudi Arabia and to receive the centralised GCC registration.